Profile | GDS2987 / GI_27735058-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 12.7 | 41 |
GSM215244 | HMVEC_vehicle_rep2 | 27.9 | 56 |
GSM215253 | HMVEC_vehicle_rep3 | 20.8 | 54 |
GSM215254 | HMVEC_atorvastatin_rep1 | 10 | 27 |
GSM215282 | HMVEC_atorvastatin_rep3 | 31.8 | 57 |
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 17.6 | 33 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 13.1 | 26 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 0.9 | 1 |
GSM215294 | HMVEC_SLx2119_rep1 | 12.1 | 41 |
GSM215295 | HMVEC_SLx2119_rep2 | 0.4 | 1 |
GSM215296 | HMVEC_SLx2119_rep3 | 27.7 | 43 |
GSM215297 | PASMC_vehicle_rep1 | 13.2 | 20 |
GSM215298 | PASMC_vehicle_rep2 | 18.5 | 28 |
GSM215310 | PASMC_vehicle_rep3 | 39.9 | 53 |
GSM215311 | PASMC_atorvastatin_rep1 | 39.8 | 56 |
GSM215312 | PASMC_atorvastatin_rep2 | 53.5 | 62 |
GSM215313 | PASMC_atorvastatin_rep3 | 31.1 | 42 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 49.4 | 61 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 19.7 | 36 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | ||
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | 21.2 | 37 |
GSM215329 | PASMC_SLx2119_rep3 | 0.4 | 1 |
GSM215330 | Fibroblasts_vehicle_rep1 | 25.4 | 50 |
GSM215331 | Fibroblasts_vehicle_rep2 | ||
GSM215332 | Fibroblasts_vehicle_rep3 | 11 | 35 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 8.9 | 24 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | ||
GSM215335 | Fibroblasts_atorvastatin_rep3 | 19.3 | 43 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 21 | 54 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 13.7 | 41 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 28.5 | 59 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 25.5 | 57 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 14.3 | 38 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 39.4 | 64 |